Results 111 to 120 of about 92,853 (340)
ESC Heart Failure, EarlyView.Our study examined the real‐world implementation of guideline‐directed medical therapy (GDMT) and its association with mortality and hospitalization in 46 816 patients with heart failure with reduced ejection fraction (HFrEF) from the Danish Heart Failure Registry (2008–2022).
Inge Schjødt +5 more
wiley +1 more source
European Thyroid JournalObjective: Patients with non-medullary thyroid carcinoma (NMTC) that are refractory to radioactive iodine (RAI) have a poor prognosis. Strategies for restoring the ability to take up iodine, so-called redifferentiation, are promising but not suitable for
Pepijn van Houten +6 more
doaj +1 more source
Improving Postdischarge Outcomes in Acute Heart Failure [PDF]
, 2018 The global burden that acute heart failure (AHF) carries has remained unchanged over the past several decades (1). European registries (2–5) showed that 1-year outcome rates remain unacceptably high (Table 1) and confirm that hospitalization for AHF ...
Ambrosy, Andrew P. +8 more
core +1 more source
ESC Heart Failure, EarlyView.Temporary RVAD support following HM3 LVAD is associated with high morbidity and mortality. Temporary RVAD support occurs most frequently in INTERMACS 1 or 2 patients and those who require pre‐operative VA‐ECMO. In addition to higher post‐operative mortality, a significantly higher risk of both dialysis and stroke at 1 year post‐implant was observed in ...
Vinh Q. Chau +12 more
wiley +1 more source
Nanocomposites, 2020 Digoxin separation from pharmaceuticals wastes, is small piece of the larger puzzle in holistic risk assessment. In this study, a novel magnetic nano composite (graphene oxide/Fe3O4/SO3H) was synthesized and used as an absorbent for the removal of ...
Paria Pashazadeh-Panahi +1 more
doaj +1 more source
Systematic review and meta-analysis of mortality and digoxin use in atrial fibrillation.
Cardiology Journal, 2016 BACKGROUND There is growing controversy regarding the association between digoxin and mortality in atrial fibrillation (AF). The aim of this analysis was to systematically review digoxin use and risk of mortality in patients with AF.
W. Qureshi +3 more
semanticscholar +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Angiotensin receptor‐neprilysin inhibitor (ARNI) therapy has demonstrated improved outcomes in heart failure with reduced ejection fraction (HFrEF). However, its benefits in patients with concomitant kidney failure undergoing replacement therapy remain uncertain. Methods and results Using the National Health Insurance Service database, we
Mi‐Hyang Jung +8 more
wiley +1 more source
Cardiology Research and Practice, 2015 Introduction. Digoxin is used to control ventricular rate in atrial fibrillation (AF). There is conflicting evidence regarding safety of digoxin. We aimed to evaluate the risk of mortality with digoxin use in patients with AF using meta-analyses. Methods.
Surbhi Chamaria +4 more
doaj +1 more source
Journal of the American College of Cardiology, 2015 The digitalis glycosides (digoxin) have been ensconced by history, efficacy, therapeutic necessity, and lack of definitive evidence as treatments for both heart failure (HF) and atrial fibrillation (AF).
Todd F. Dardas, Wayne C. Levy
openaire +3 more sources
Drug interaction study in hospitalized hepatic cirrhosis patient in Dr.Ramelan navy hospital [PDF]
, 2009 Cirrhotic liver lead to some changes in pathophysiology such as reduction in liver blood flow, decrease some metabolic and synthetic function of the liver. Also there is a change in endothelial lining from hepatic sinusoid.
., Widyati +3 more
core